Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2025
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three subtypes: constipation-predominant, diarrhea-predominant, and mixed. This analysis focuses on the diarrhea-predominant subtype (IBS-D). Available treatments are limited; few drugs have FDA approval for IBS-D, and most drugs are used off-label. The primary focus remains on alleviating diarrhea symptoms while providing psychological support to patients. Various approaches include the use of antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), a 5-HTR modulator (Sebela Pharmaceuticals’ Lotronex), an antibiotic (Salix Pharmaceuticals’ Xifaxan), and an opioid delta receptor antagonist (AbbVie’s Viberzi).
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-D patients?
- How have Viberzi and Lotronex been integrated into the treatment algorithm, and what is their source of business?
- What percentage of IBS-D patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of IBS-D patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Markets covered: United States
Key companies: AbbVie, Salix, Sebela Pharmaceuticals
Key drugs: Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulfate / scopolamine, SSRIs, SNRIs, tricyclic antidepressants.
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
